Gemcitabine (GEM) resistance is one of the major causes of treatment failure in pancreatic
ductal adenocarcinoma (PDAC) in clinic. Here, through CRISPR/Cas9 activation library …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most life-threatening malignancies.
Although the deoxycytidine analog gemcitabine has been used as the first-line treatment for …

Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal
cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for …

Simple Summary Pancreatic cancer is one of the most lethal cancers. Although complete
surgical resection is the only curative treatment for pancreatic cancer, a late diagnosis is …

Abstract Gemcitabine, 2′, 2′-difluoro-2′-deoxycytidine, is used as a pro-drug in
treatment of variety of solid tumour cancers including pancreatic cancer. After intake …

Background Pancreatic ductal adenocarcinoma (PDAC) patients suffer poor outcomes,
including a five-year survival of below 10%. Poor outcomes result in part from therapeutic …

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to
treat. Due to the asymptomatic nature of the disease and lack of curative treatment …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer most frequently
detected at an advanced stage that limits treatment options to systemic chemotherapy, which …

Gemcitabine‐based chemotherapy is the first‐line treatment for pancreatic cancer. However,
chemoresistance is a major obstacle to drug efficacy, leading to poor prognosis. Little …

The chemoresistance of tumor cells is one of the most urgent challenges in modern
oncology and in pancreatic cancer, in which this problem is the most prominent. Therefore …